United Therapeutics’ (UTHR) third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings rose 19% year over year on the back of higher product sales.Revenues totaled $748.9 million, which beat the Zacks Consensus Estimate of $717.5 million. Revenues rose 23% year over year, driven by meaningful growth of key products — Tyvaso, Orenitram and Unituxin.See the Zacks Earnings Calendar to stay ahead of market-making news.More on UTHR’s EarningsUnited Therapeutics markets fo ...